ImmunoGen, Inc. (NASDAQ:IMGN) reached a new 52-week high on Monday . The stock traded as high as $10.07 and last traded at $8.91, with a volume of 3699100 shares. The stock had previously closed at $8.91.

Several research firms recently weighed in on IMGN. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $12.00 price objective on shares of ImmunoGen in a report on Thursday, February 8th. HC Wainwright set a $18.00 price objective on shares of ImmunoGen and gave the stock a “buy” rating in a report on Monday. BidaskClub raised shares of ImmunoGen from a “buy” rating to a “strong-buy” rating in a report on Friday, February 9th. Zacks Investment Research raised shares of ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a report on Tuesday, October 31st. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $5.00 price objective on shares of ImmunoGen in a report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $9.10.

The company has a debt-to-equity ratio of -0.03, a quick ratio of 2.78 and a current ratio of 2.81.

ImmunoGen (NASDAQ:IMGN) last issued its quarterly earnings results on Friday, February 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $39.40 million for the quarter, compared to analysts’ expectations of $39.62 million. During the same quarter in the previous year, the business posted ($0.39) EPS. The company’s quarterly revenue was up 185.5% compared to the same quarter last year. equities analysts forecast that ImmunoGen, Inc. will post -1.01 EPS for the current year.

A number of institutional investors have recently modified their holdings of IMGN. Arrowstreet Capital Limited Partnership bought a new stake in ImmunoGen in the second quarter worth about $102,000. Intl Fcstone Inc. bought a new stake in ImmunoGen in the second quarter worth about $115,000. SG Americas Securities LLC raised its position in ImmunoGen by 75.7% in the fourth quarter. SG Americas Securities LLC now owns 18,416 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 7,937 shares in the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in ImmunoGen during the 2nd quarter worth about $126,000. Finally, Virginia Retirement Systems ET AL acquired a new stake in ImmunoGen during the 3rd quarter worth about $136,000. Hedge funds and other institutional investors own 67.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “ImmunoGen (IMGN) Sets New 1-Year High at $10.07” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2018/02/14/immunogen-imgn-sets-new-1-year-high-at-10-07.html.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.